Morepen Laboratories Launches First US Prescription Generic Drug, Plans Further Filings
Morepen Laboratories has launched its first prescription generic drug, Desloratadine Tablets USP 5 mg, in the US market through its wholly owned subsidiary, Morepen Bio Inc. Available in 100-count and 500-count packs, this launch extends Morepen's presence from supplying active pharmaceutical ingredients to finished-dosage medicines and distribution. The company has also submitted an Abbreviated New Drug Application for Sitagliptin Phosphate Tablets, currently under US FDA review, and plans further filings to expand its US prescription generics business.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 38/100.
Outlets measured: thetribune, economictimes, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 9 Nov, 04:13 am. Other outlets followed.